F GrandMaison
Overview
Explore the profile of F GrandMaison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spelman T, Herring W, Acosta C, Hyde R, Jokubaitis V, Pucci E, et al.
J Med Econ
. 2023 Dec;
27(1):109-125.
PMID: 38085684
Aim: To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis...
2.
Lefort M, Sharmin S, Andersen J, Vukusic S, Casey R, Debouverie M, et al.
BMC Med Res Methodol
. 2022 May;
22(1):155.
PMID: 35637426
Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment...
3.
Freedman M, Duquette P, GrandMaison F, Lee L, Vorobeychik G, Lara N, et al.
Curr Med Res Opin
. 2019 Jan;
35(5):767-776.
PMID: 30614288
Background: There is limited evidence on the effectiveness and healthcare costs of switching to fingolimod versus another first line injectable therapy (FLIT) in patients with relapsing multiple sclerosis (RMS) who...
4.
Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, et al.
Eur J Neurol
. 2018 Oct;
26(2):363-370.
PMID: 30298572
Background And Purpose: Treatment options in primary progressive multiple sclerosis (PPMS) are scarce and, with the exception of ocrelizumab, anti-inflammatory agents have failed to show efficacy in ameliorating disability progression....
5.
Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, et al.
Eur J Neurol
. 2016 Jan;
23(4):729-36.
PMID: 26782663
Background And Purpose: Early relapse outcomes in long-term stable patients switching from interferon β/glatiramer acetate (IFNβ/GA) to oral therapy are unknown. Objective: The objective of this study was to compare...
6.
Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, GrandMaison F, et al.
Eur J Neurol
. 2015 Mar;
22(6):981-9.
PMID: 25808578
Background And Purpose: Early prediction of long-term disease evolution is a major challenge in the management of multiple sclerosis (MS). Our aim was to predict the natural course of MS...
7.
Verheul F, Smolders J, Trojano M, Lepore V, Zwanikken C, Amato M, et al.
Acta Neurol Scand
. 2012 Sep;
127(5):301-8.
PMID: 22970985
Background: Patients with multiple sclerosis (MS) are more frequently born in spring when compared to autumn. Fluctuation of UV-light has been hypothesized to drive this phenomenon. Aim: To assess the...
8.
Jacques F, Gaboury I, Christie S, GrandMaison F
Mult Scler Int
. 2012 Sep;
2012:935921.
PMID: 22966460
Tacrolimus is a calcineurin inhibitor which works to induce immune suppression by preventing cytokine transcription and lymphocyte activation. Combining the immunomodulator interferon beta-1b (Betaseron) with the immunosuppressant tacrolimus (Prograf) may...
9.
Lechner-Scott J, Spencer B, DE Malmanche T, Attia J, Fitzgerald M, Trojano M, et al.
Mult Scler
. 2011 Dec;
18(7):974-82.
PMID: 22185806
Background: With the advent of MRI scanning, the value of lumbar puncture to assess oligoclonal band (OCB) status-for the diagnosis of multiple sclerosis (MS) is increasingly uncertain. One major issue...
10.
Banwell B, Kennedy J, Sadovnick D, Arnold D, Magalhaes S, Wambera K, et al.
Neurology
. 2009 Jan;
72(3):232-9.
PMID: 19153370
Background: The incidence of acquired demyelination of the CNS (acquired demyelinating syndromes [ADS]) in children is unknown. It is important that physicians recognize the features of ADS to facilitate care...